{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:38:56Z","timestamp":1793392736543,"version":"4.5.0"},"reference-count":55,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>With the recent introduction of a number of highly effective disease-modifying treatments\n(DMTs) and the resulting almost complete prevention of acute relapses in many patients with multiple\nsclerosis (MS), the interest of MS clinicians has gradually shifted from relapse prevention to\ncounteraction of disease progression and the treatment of residual symptoms. Targeting the cannabinoid\nsystem with nabiximols is an approved and effective strategy for the treatment of spasticity\nsecondary to MS. Recently, the concept of spasticity plus syndrome (SPS) was introduced to account\nfor the evidence that spasticity often appears in MS patients in clusters with other symptoms (such as\npain, bladder dysfunction, sleep, and mood disorders), where cannabinoids can also be effective due\nto their broader action on many immune and neuronal functions. Interestingly, outside these symptomatic\nbenefits, extensive pre-clinical and clinical research indicated how the modulation of the\ncannabinoid system results in significant anti-inflammatory and neuroprotective effects, all potentially\nrelevant for MS disease control. This evidence makes nabiximols a potential disease modifying\nsymptomatic treatment (DMST), a concept introduced in an attempt to overcome the often artificial\ndistinction between DMTs and symptomatic therapies (STs).<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/011570159x329058240820070701","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T09:13:08Z","timestamp":1726477988000},"page":"503-510","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Disease-Modifying Symptomatic Treatment (DMST) Potential of Cannabinoids in Patients with Multiple Sclerosis"],"prefix":"10.2174","volume":"23","author":[{"given":"Antonio","family":"Bruno","sequence":"first","affiliation":[{"name":"Neurology Unit, IRCCS Neuromed, Pozzilli (IS), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Annovazzi","sequence":"additional","affiliation":[{"name":"Neuroimmunology Unit, Multiple Sclerosis Centre ASST Valle\nOlona, Gallarate Hospital, Gallarate (VA), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinella","family":"Clerico","sequence":"additional","affiliation":[{"name":"Clinical and Biological Sciences Department, University of Torino,\nCagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Cocco","sequence":"additional","affiliation":[{"name":"Centro Sclerosi Multipla, Department of Medical Science and Public Health, University of Cagliari,\nCagliari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Conte","sequence":"additional","affiliation":[{"name":"Neurology Unit, IRCCS Neuromed, Pozzilli (IS), Italy"},{"name":"Department of Human Neurosciences, Sapienza, University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girolama Alessandra","family":"Marfia","sequence":"additional","affiliation":[{"name":"Department of\nSystems Medicine, Tor Vergata University, Rome, Italy"},{"name":"Multiple Sclerosis Clinical and Research Unit, Tor Vergata\nUniversity Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Salvetti","sequence":"additional","affiliation":[{"name":"Neurology Unit, IRCCS Neuromed, Pozzilli (IS), Italy"},{"name":"Centre for Experimental Neurological Therapies (CENTERS), Department of Neurosciences,\nMental Health and Sensory Organs, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Tomassini","sequence":"additional","affiliation":[{"name":"Institute of Advanced Biomedical\nTechnologies (ITAB), Department of Neurosciences, Imaging and Clinical Sciences, University G. d\u2019Annunzio of\nChieti-Pescara, Chieti, Abruzzo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina Torri","family":"Clerici","sequence":"additional","affiliation":[{"name":"Neuroimmunology Unit, IRCCS Istituto Neurologico C. Besta, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Totaro","sequence":"additional","affiliation":[{"name":"Demyelinating Disease Center, Department of Neurology, San Salvatore Hospital, L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettore","family":"Dolcetti","sequence":"additional","affiliation":[{"name":"Neurology Unit, IRCCS Neuromed, Pozzilli (IS), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Centonze","sequence":"additional","affiliation":[{"name":"Neurology Unit, IRCCS Neuromed, Pozzilli (IS), Italy"},{"name":"Department of\nSystems Medicine, Tor Vergata University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"325","author":"McGinley M.P.","year":"2021","unstructured":"McGinley M.P.; Goldschmidt C.H.; Rae-Grant A.D.; Diagnosis and treatment of multiple sclerosis. JAMA  2021,325(8),765-779","journal-title":"JAMA"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"CD013444","DOI":"10.1002\/14651858.CD013444.pub2","volume":"5","author":"Filippini G.","year":"2022","unstructured":"Filippini G.; Minozzi S.; Borrelli F.; Cinquini M.; Dwan K.; Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. Cochrane Libr  2022,5(5),CD013444","journal-title":"Cochrane Libr"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"104711","DOI":"10.1016\/j.msard.2023.104711","volume":"74","author":"Torri C.V.","year":"2023","unstructured":"Torri C.V.; Brambilla L.; Politi P.L.; Viggiani F.; Mercurio S.; Tonietti S.; Ronzoni M.; Crisafulli S.G.; Antozzi C.; Tramacere I.; Redemagni C.; Confalonieri P.; Nabiximols oromucosal spray in patients with multiple sclerosis-related bladder dysfunction: A prospective study. Mult Scler Relat Disord  2023,74,104711","journal-title":"Mult Scler Relat Disord"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1177\/1352458520926869","volume":"27","author":"Wiendl H.","year":"2021","unstructured":"Wiendl H.; Spelman T.; Butzkueven H.; Kappos L.; Trojano M.; Su R.; Campbell N.; Ho P.R.; Licata S.; Real-world disability improvement in patients with relapsing\u2013remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program. Mult Scler  2021,27(5),719-728","journal-title":"Mult Scler"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"480","DOI":"10.5603\/PJNNS.a2022.0068","volume":"56","author":"Piasecka-Stryczy\u0144ska K.","year":"2022","unstructured":"Piasecka-Stryczy\u0144ska K.; Kaczy\u0144ski \u0141.; Rolka M.; Homa M.; Sta\u015bkiewicz W.; Paczwa P.; W\u00f3jcik R.; Kaczor M.P.; Rejdak K.; Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis. Neurol Neurochir Pol  2022,56(6),480-489","journal-title":"Neurol Neurochir Pol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"802918","DOI":"10.3389\/fneur.2021.802918","volume":"12","author":"Bruno A.","year":"2022","unstructured":"Bruno A.; Dolcetti E.; Centonze D.; Theoretical and therapeutic implications of the spasticity-plus syndrome model in multiple sclerosis. Front Neurol  2022,12,802918","journal-title":"Front Neurol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2217\/nmt-2022-0002","volume":"12","author":"Chan A.","year":"2022","unstructured":"Chan A.; Silv\u00e1n C.V.; Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: A 10-year recap. Neurodegener Dis Manag  2022,12(3),141-154","journal-title":"Neurodegener Dis Manag"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1111\/ene.15412","volume":"29","author":"Patti F.","year":"2022","unstructured":"Patti F.; Chisari C.G.; Fern\u00e1ndez \u00d3.; Sarroca J.; Ferrer-Pic\u00f3n E.; Hern\u00e1ndez V.F.; Vila Silv\u00e1n C.; A real\u2010world evidence study of nabiximols in multiple sclerosis patients with resistant spasticity: Analysis in relation to the newly described \u2018spasticity\u2010plus syndrome\u2019. Eur J Neurol  2022,29(9),2744-2753","journal-title":"Eur J Neurol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fneur.2020.00152","volume":"11","author":"Fern\u00e1ndez \u00d3.","year":"2020","unstructured":"Fern\u00e1ndez \u00d3.; Costa-Frossard L.; Mart\u00ednez-Gin\u00e9s M.; Montero P.; Prieto J.M.; Rami\u00f3 L.; The broad concept of \u201cspasticity-plus syndrome\u201d in multiple sclerosis: A possible new concept in the management of multiple sclerosis symptoms. Front Neurol  2020,11,152","journal-title":"Front Neurol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1191\/1352458504ms1048oa","volume":"10","author":"Vaney C.","year":"2004","unstructured":"Vaney C.; Heinzel-Gutenbrunner M.; Jobin P.; Tschopp F.; Gattlen B.; Hagen U.; Schnelle M.; Reif M.; Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled, crossover study. Mult Scler  2004,10(4),417-424","journal-title":"Mult Scler"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1136\/jnnp.2005.070136","volume":"76","author":"Zajicek J.P.","year":"2005","unstructured":"Zajicek J.P.; Sanders H.P.; Wright D.E.; Vickery P.J.; Ingram W.M.; Reilly S.M.; Nunn A.J.; Teare L.J.; Fox P.J.; Thompson A.J.; Cannabinoids in multiple sclerosis (CAMS) study: Safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry  2005,76(12),1664-1669","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2055217320959816","DOI":"10.1177\/2055217320959816","volume":"6","author":"Braley T.J.","year":"2020","unstructured":"Braley T.J.; Whibley D.; Alschuler K.N.; Ehde D.M.; Chervin R.D.; Clauw D.J.; Williams D.; Kratz A.L.; Cannabinoid use among Americans with MS: Current trends and gaps in knowledge. Mult Scler J Exp Transl Clin  2020,6(3),2055217320959816","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1468-1331.2010.03328.x","volume":"18","author":"Novotna A.","year":"2011","unstructured":"Novotna A.; Mares J.; Ratcliffe S.; Novakova I.; Vachova M.; Zapletalova O.; Gasperini C.; Pozzilli C.; Cefaro L.; Comi G.; Rossi P.; Ambler Z.; Stelmasiak Z.; Erdmann A.; Montalban X.; Klimek A.; Davies P.; A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex\u00ae), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol  2011,18(9),1122-1131","journal-title":"Eur J Neurol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1179\/016164109X12590518685660","volume":"32","author":"Collin C.","year":"2010","unstructured":"Collin C.; Ehler E.; Waberzinek G.; Alsindi Z.; Davies P.; Powell K.; Notcutt W.; O\u2019Leary C.; Ratcliffe S.; Nov\u00e1kov\u00e1 I.; Zapletalova O.; Pikov\u00e1 J.; Ambler Z.; A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res  2010,32(5),451-459","journal-title":"Neurol Res"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1136\/jnnp-2015-312591","volume":"87","author":"Patti F.","year":"2016","unstructured":"Patti F.; Messina S.; Solaro C.; Amato M.P.; Bergamaschi R.; Bonavita S.; Bruno B.R.; Brescia M.V.; Costantino G.F.; Cavalla P.; Centonze D.; Comi G.; Cottone S.; Danni M.; Francia A.; Gajofatto A.; Gasperini C.; Ghezzi A.; Iudice A.; Lus G.; Maniscalco G.T.; Marrosu M.G.; Matta M.; Mirabella M.; Montanari E.; Pozzilli C.; Rovaris M.; Sessa E.; Spitaleri D.; Trojano M.; Valentino P.; Zappia M.; Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J Neurol Neurosurg Psychiatry  2016,87(9),944-951","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000360285","volume":"72","author":"Flachenecker P.","year":"2014","unstructured":"Flachenecker P.; Henze T.; Zettl U.K.; Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol\/cannabidiol oromucosal spray) in clinical practice. Eur Neurol  2014,72(1-2),95-102","journal-title":"Eur Neurol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/medicines5030059","volume":"5","author":"Turri M.","year":"2018","unstructured":"Turri M.; Teatini F.; Donato F.; Zanette G.; Tugnoli V.; Deotto L.; Bonetti B.; Squintani G.; Pain modulation after oromucosal cannabinoid spray (SATIVEX\u00ae) in patients with multiple sclerosis: A study with quantitative sensory testing and laser-evoked potentials. Medicines  2018,5(3),59","journal-title":"Medicines"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"pnv080","DOI":"10.1093\/pm\/pnv080","volume":"17","author":"Russo M.","year":"2016","unstructured":"Russo M.; Naro A.; Leo A.; Sessa E.; D\u2019Aleo G.; Bramanti P.; Calabr\u00f2 R.S.; Evaluating Sativex\u00ae in neuropathic pain management: A clinical and neurophysiological assessment in multiple sclerosis. Pain Med  2016,17(6),pnv080","journal-title":"Pain Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1007\/s00415-012-6739-4","volume":"260","author":"Langford R.M.","year":"2013","unstructured":"Langford R.M.; Mares J.; Novotna A.; Vachova M.; Novakova I.; Notcutt W.; Ratcliffe S.; A double-blind, randomized, placebo-controlled, parallel-group study of THC\/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol  2013,260(4),984-997","journal-title":"J Neurol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.ejpain.2008.05.014","volume":"13","author":"Conte A.","year":"2009","unstructured":"Conte A.; Bettolo C.M.; Onesti E.; Frasca V.; Iacovelli E.; Gilio F.; Giacomelli E.; Gabriele M.; Aragona M.; Tomassini V.; Pantano P.; Pozzilli C.; Inghilleri M.; Cannabinoid\u2010induced effects on the nociceptive system: A neurophysiological study in patients with secondary progressive multiple sclerosis. Eur J Pain  2009,13(5),472-477","journal-title":"Eur J Pain"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1177\/1352458510378020","volume":"16","author":"Kavia R.B.C.","year":"2010","unstructured":"Kavia R.B.C.; De Ridder D.; Constantinescu C.S.; Stott C.G.; Fowler C.J.; Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler  2010,16(11),1349-1359","journal-title":"Mult Scler"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10072-017-3148-6","volume":"39","author":"Maniscalco G.T.","year":"2018","unstructured":"Maniscalco G.T.; Aponte R.; Bruzzese D.; Guarcello G.; Manzo V.; Napolitano M.; Moreggia O.; Chiariello F.; Florio C.; THC\/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: A pilot prospective study. Neurol Sci  2018,39(1),97-102","journal-title":"Neurol Sci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.neuropharm.2014.01.007","volume":"79","author":"Musella A.","year":"2014","unstructured":"Musella A.; Sepman H.; Mandolesi G.; Gentile A.; Fresegna D.; Haji N.; Conrad A.; Lutz B.; Maccarrone M.; Centonze D.; Pre- and postsynaptic type-1 cannabinoid receptors control the alterations of glutamate transmission in experimental autoimmune encephalomyelitis. Neuropharmacology  2014,79,567-572","journal-title":"Neuropharmacology"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.pneurobio.2017.10.007","volume":"160","author":"Chiurchi\u00f9 V.","year":"2018","unstructured":"Chiurchi\u00f9 V.; van der Stelt M.; Centonze D.; Maccarrone M.; The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases. Prog Neurobiol  2018,160,82-100","journal-title":"Prog Neurobiol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1093\/brain\/awm160","volume":"130","author":"Centonze D.","year":"2007","unstructured":"Centonze D.; Bari M.; Rossi S.; Prosperetti C.; Furlan R.; Fezza F.; De Chiara V.; Battistini L.; Bernardi G.; Bernardini S.; Martino G.; Maccarrone M.; The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain  2007,130(10),2543-2553","journal-title":"Brain"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"e82848","DOI":"10.1371\/journal.pone.0082848","volume":"8","author":"Rossi S.","year":"2013","unstructured":"Rossi S.; Bozzali M.; Bari M.; Mori F.; Studer V.; Motta C.; Buttari F.; Cercignani M.; Gravina P.; Mastrangelo N.; Castelli M.; Mancino R.; Nucci C.; Sottile F.; Bernardini S.; Maccarrone M.; Centonze D.; Association between a genetic variant of type-1 cannabinoid receptor and inflammatory neurodegeneration in multiple sclerosis. PLoS One  2013,8(12),e82848","journal-title":"PLoS One"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1093\/brain\/awg224","volume":"126","author":"Pryce G.","year":"2003","unstructured":"Pryce G.; Ahmed Z.; Hankey D.J.R.; Jackson S.J.; Croxford J.L.; Pocock J.M.; Ledent C.; Petzold A.; Thompson A.J.; Giovannoni G.; Cuzner M.L.; Baker D.; Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain  2003,126(10),2191-2202","journal-title":"Brain"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/antiox11102049","volume":"11","author":"Tadijan A.","year":"2022","unstructured":"Tadijan A.; Vla\u0161i\u0107 I.; Vlaini\u0107 J.; \u0110iki\u0107 D.; Or\u0161oli\u0107 N.; Jazvin\u0161\u0107ak Jembrek M.; Intracellular molecular targets and signaling pathways involved in antioxidative and neuroprotective effects of cannabinoids in neurodegenerative conditions. Antioxidants  2022,11(10),2049","journal-title":"Antioxidants"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.bbi.2011.01.020","volume":"25","author":"Correa F.","year":"2011","unstructured":"Correa F.; Hernang\u00f3mez-Herrero M.; Mestre L.; Lor\u00eda F.; Docagne F.; Guaza C.; The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: Evidence for a cross-talk between IL-12p70\/IL-23 axis and IL-10 in microglial cells. Brain Behav Immun  2011,25(4),736-749","journal-title":"Brain Behav Immun"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/glia.22366","volume":"60","author":"Hernang\u00f3mez M.","year":"2012","unstructured":"Hernang\u00f3mez M.; Mestre L.; Correa F.G.; Lor\u00eda F.; Mecha M.; I\u00f1igo P.M.; Docagne F.; Williams R.O.; Borrell J.; Guaza C.; CD200\u2010CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation. Glia  2012,60(9),1437-1450","journal-title":"Glia"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.brainres.2011.03.020","volume":"1390","author":"Lourbopoulos A.","year":"2011","unstructured":"Lourbopoulos A.; Grigoriadis N.; Lagoudaki R.; Touloumi O.; Polyzoidou E.; Mavromatis I.; Tascos N.; Breuer A.; Ovadia H.; Karussis D.; Shohami E.; Mechoulam R.; Simeonidou C.; Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis. Brain Res  2011,1390,126-141","journal-title":"Brain Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/j.1476-5381.2011.01379.x","volume":"163","author":"Kozela E.","year":"2011","unstructured":"Kozela E.; Lev N.; Kaushansky N.; Eilam R.; Rimmerman N.; Levy R.; Ben-Nun A.; Juknat A.; Vogel Z.; Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis\u2010like disease in C57BL\/6 mice. Br J Pharmacol  2011,163(7),1507-1519","journal-title":"Br J Pharmacol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.msard.2015.08.001","volume":"4","author":"Moreno-Martet M.","year":"2015","unstructured":"Moreno-Martet M.; Feli\u00fa A.; Espejo-Porras F.; Mecha M.; Carrillo-Salinas F.J.; Fern\u00e1ndez-Ruiz J.; Guaza C.; de Lago E.; The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to \u0394-tetrahydrocannabinol acting through CB1 receptors. Mult Scler Relat Disord  2015,4(6),505-511","journal-title":"Mult Scler Relat Disord"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1111\/bph.13159","volume":"172","author":"Feli\u00fa A.","year":"2015","unstructured":"Feli\u00fa A.; Moreno-Martet M.; Mecha M.; Carrillo-Salinas F.J.; de Lago E.; Fern\u00e1ndez-Ruiz J.; Guaza C.A.; Sativex\u00ae\u2010like combination of phytocannabinoids as a disease\u2010modifying therapy in a viral model of multiple sclerosis. Br J Pharmacol  2015,172(14),3579-3595","journal-title":"Br J Pharmacol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1212\/NXI.0000000000000048","volume":"1","author":"Mori F.","year":"2014","unstructured":"Mori F.; Ljoka C.; Nicoletti C.G.; Kusayanagi H.; Buttari F.; Giordani L.; Rossi S.; Foti C.; Centonze D.; CB1 receptor affects cortical plasticity and response to physiotherapy in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm  2014,1(4),e48","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"101494","DOI":"10.1016\/j.msard.2019.101494","volume":"38","author":"Baione V.","year":"2020","unstructured":"Baione V.; Belvisi D.; Cortese A.; Cetta I.; Tartaglia M.; Millefiorini E.; Berardelli A.; Conte A.; Cortical M1 plasticity and metaplasticity in patients with multiple sclerosis. Mult Scler Relat Disord  2020,38,101494","journal-title":"Mult Scler Relat Disord"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/B978-0-12-819410-2.00024-2","volume":"184","author":"Stampanoni B.M.","year":"2022","unstructured":"Stampanoni B.M.; Iezzi E.; Centonze D.; Multiple sclerosis: Inflammation, autoimmunity and plasticity. Handb Clin Neurol  2022,184,457-470","journal-title":"Handb Clin Neurol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"a039743","DOI":"10.1101\/cshperspect.a039743","volume":"11","author":"Hoffman A.F.","year":"2021","unstructured":"Hoffman A.F.; Hwang E.K.; Lupica C.R.; Impairment of synaptic plasticity by cannabis, \u03949-THC, and synthetic cannabinoids. Cold Spring Harb Perspect Med  2021,11(5),a039743","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.brs.2009.03.001","volume":"2","author":"Koch G.","year":"2009","unstructured":"Koch G.; Mori F.; Codec\u00e0 C.; Kusayanagi H.; Monteleone F.; Buttari F.; Fiore S.; Bernardi G.; Centonze D.; Cannabis-based treatment induces polarity-reversing plasticity assessed by theta burst stimulation in humans. Brain Stimul  2009,2(4),229-233","journal-title":"Brain Stimul"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1177\/1352458517721358","volume":"24","author":"Stampanoni B.M.","year":"2018","unstructured":"Stampanoni B.M.; Leocani L.; Comi G.; Iezzi E.; Centonze D.; Can pharmacological manipulation of LTP favor the effects of motor rehabilitation in multiple sclerosis? Mult Scler  2018,24(7),902-907","journal-title":"Mult Scler"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1177\/1352458513512541","volume":"20","author":"Mori F.","year":"2014","unstructured":"Mori F.; Kusayanagi H.; Nicoletti C.G.; Weiss S.; Marciani M.G.; Centonze D.; Cortical plasticity predicts recovery from relapse in multiple sclerosis. Mult Scler  2014,20(4),451-457","journal-title":"Mult Scler"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.bbi.2011.03.017","volume":"25","author":"Rossi S.","year":"2011","unstructured":"Rossi S.; Furlan R.; Chiara V.D.; Muzio L.; Musella A.; Motta C.; Studer V.; Cavasinni F.; Bernardi G.; Martino G.; Cravatt B.F.; Lutz B.; Maccarrone M.; Centonze D.; Cannabinoid CB1 receptors regulate neuronal TNF-\u03b1 effects in experimental autoimmune encephalomyelitis. Brain Behav Immun  2011,25(6),1242-1248","journal-title":"Brain Behav Immun"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/ijms21010143","volume":"21","author":"Stampanoni B.M.","year":"2019","unstructured":"Stampanoni B.M.; Iezzi E.; Pavone L.; Mandolesi G.; Musella A.; Gentile A.; Gilio L.; Centonze D.; Buttari F.; Modeling resilience to damage in multiple sclerosis: Plasticity meets connectivity. Int J Mol Sci  2019,21(1),143","journal-title":"Int J Mol Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12883-023-03171-0","volume":"23","author":"Gajofatto A.","year":"2023","unstructured":"Gajofatto A.; Cardobi N.; Gobbin F.; Calabrese M.; Turatti M.; Benedetti M.D.; Resting-state functional connectivity in multiple sclerosis patients receiving nabiximols for spasticity. BMC Neurol  2023,23(1),128","journal-title":"BMC Neurol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.17653\/2374-9091.SS0005","volume":"1","author":"Tomassini V.","year":"2014","unstructured":"Tomassini V.; Onesti E.; Tinelli E.; Frasca V.; Antonilli L.; Aragona M.; Lopergolo D.; Capua G.; Pozzilli C.; Pantano P.; Inghilleri M.; Assessing the neurophysiological effects of cannabinoids on spasticity in multiple sclerosis. J Neurosci Rehabil  2014,1(2),1-3","journal-title":"J Neurosci Rehabil"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.3390\/ijms24021639","volume":"24","author":"Schwarz K.","year":"2023","unstructured":"Schwarz K.; Schmitz F.; Synapse dysfunctions in multiple sclerosis. Int J Mol Sci  2023,24(2),1639","journal-title":"Int J Mol Sci"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.nbd.2017.07.019","volume":"108","author":"Mandolesi G.","year":"2017","unstructured":"Mandolesi G.; Bullitta S.; Fresegna D.; Gentile A.; De Vito F.; Dolcetti E.; Rizzo F.R.; Strimpakos G.; Centonze D.; Musella A.; Interferon-\u03b3 causes mood abnormalities by altering cannabinoid CB1 receptor function in the mouse striatum. Neurobiol Dis  2017,108,45-53","journal-title":"Neurobiol Dis"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1111\/febs.15907","volume":"289","author":"Robledo-Menendez A.","year":"2022","unstructured":"Robledo-Menendez A.; Vella M.; Grandes P.; Soria-Gomez E.; Cannabinoid control of hippocampal functions: The where matters. FEBS J  2022,289(8),2162-2175","journal-title":"FEBS J"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3389\/fneur.2019.00153","volume":"10","author":"Petsas N.","year":"2019","unstructured":"Petsas N.; De Giglio L.; Gonz\u00e1lez-Quintanilla V.; Giuliani M.; De Angelis F.; Tona F.; Carmellini M.; Mainero C.; Pozzilli C.; Pantano P.; Functional connectivity changes after initial treatment with fingolimod in multiple sclerosis. Front Neurol  2019,10,153","journal-title":"Front Neurol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1476-5381.2011.01579.x","volume":"165","author":"Rossi S.","year":"2012","unstructured":"Rossi S.; Lo Giudice T.; De Chiara V.; Musella A.; Studer V.; Motta C.; Bernardi G.; Martino G.; Furlan R.; Martorana A.; Centonze D.; Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis. Br J Pharmacol  2012,165(4),861-869","journal-title":"Br J Pharmacol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jneuroim.2013.08.009","volume":"264","author":"Musella A.","year":"2013","unstructured":"Musella A.; Mandolesi G.; Gentile A.; Rossi S.; Studer V.; Motta C.; Sepman H.; Fresegna D.; Haji N.; Paolillo A.; Matarese G.; Centonze D.; Cladribine interferes with IL-1\u03b2 synaptic effects in experimental multiple sclerosis. J Neuroimmunol  2013,264(1-2),8-13","journal-title":"J Neuroimmunol"},{"key":"ref=52","first-page":"163","volume":"27","author":"Mori F.","year":"2012","unstructured":"Mori F.; Kusayanagi H.; Buttari F.; Centini B.; Monteleone F.; Nicoletti C.G.; Bernardi G.; Di Cantogno E.V.; Marciani M.G.; Centonze D.; Early treatment with high-dose interferon beta-1a reverses cognitive and cortical plasticity deficits in multiple sclerosis. Funct Neurol  2012,27(3),163-168","journal-title":"Funct Neurol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jamaneurol.2022.4655","volume":"80","author":"Tur C.","year":"2023","unstructured":"Tur C.; Carbonell-Mirabent P.; Cobo-Calvo \u00c1.; Otero-Romero S.; Arrambide G.; Midaglia L.; Castill\u00f3 J.; Vidal-Jordana \u00c1.; Rodr\u00edguez-Acevedo B.; Zabalza A.; Gal\u00e1n I.; Nos C.; Salerno A.; Auger C.; Pareto D.; Comabella M.; R\u00edo J.; Sastre-Garriga J.; Rovira \u00c0.; Tintor\u00e9 M.; Montalban X.; Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis. JAMA Neurol  2023,80(2),151-160","journal-title":"JAMA Neurol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.brainresbull.2016.04.004","volume":"124","author":"Nazari M.","year":"2016","unstructured":"Nazari M.; Keshavarz S.; Rafati A.; Namavar M.R.; Haghani M.; Fingolimod (FTY720) improves hippocampal synaptic plasticity and memory deficit in rats following focal cerebral ischemia. Brain Res Bull  2016,124,95-102","journal-title":"Brain Res Bull"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"e8826","DOI":"10.1097\/MD.0000000000008826","volume":"96","author":"Russo M.","year":"2017","unstructured":"Russo M.; Dattola V.; Logiudice A.L.; Ciurleo R.; Sessa E.; De Luca R.; Bramanti P.; Bramanti A.; Naro A.; Calabr\u00f2 R.S.; The role of Sativex in robotic rehabilitation in individuals with multiple sclerosis. Medicine  2017,96(46),e8826","journal-title":"Medicine"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/011570159X329058240820070701","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/234061\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/011570159X329058240820070701","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T05:06:04Z","timestamp":1742187964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/234061\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/011570159x329058240820070701","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}